The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Chester, Bermuda
That covers it. I usually use Microsoft word to proof read back my own work. I will do the same with RNS’s from now on! The devil is in the detail as always. Still I am very patient so no big deal.
ATB
Evening guys,just maybe Lindy has decided given the change in circumstances stemming from South Africa, to just go with the 16 patients for now until we hear differently??
Hi BOJO2020
How you have read it is exactly the way I did for the first two readings but it does say post period and an interim report can look forward as well as back. So it is pretty convincing that its 16 up to and including the 22nd January.
I was surprised as Prof. Durrant was looking so positive in that presentation.
We can only conclude that the difficulties in South Africa meant the clinic was unable to continue in the days post the AGM presentation.
We need to look at how things are in SA right now to gauge if things are back on track.
I am sure the company will let us all know in due course.
ATB
Chester.
BOJO
I like your optimism but the figure of 16 patients is firstly mentioned under the highlights section and you'll notice the words '(including post period)' by the title. Then later under the Covidity section they clearly say 16 patients 'to date'. So either it definitely is up to 22nd Jan or it's very badly drafted. Pretty sure it's the former.
Am I missing something? Blinded by hope maybe!
The report was up to Nov 21. Hence 16 covidity subjects dosed as confirmed by our CEO on 3rd of December 21. So how do we arrive at still only 16 subjects dosed in the Covidity trial to date? An assumption? Ok I realise that there has been no indication that more than 16 subjects have been dosed. It would therefore also be an assumption to say more have since been dosed, but the report is not up to Jan 22 is it.
I have read the RNS several times. Like I say, maybe with rose tinted glasses? I followed the link on the website but still no clearer to me.
If this is any reliable indication then it looks relatively hopeful.
https://www.bbc.co.uk/news/uk-51768274
Chester - agree. Re the Modi1 trial start ... from memory the "lead hospital" was in Liverpool ??
It would be interesting to drill down and see the local Covid rates for this area which may give a guide as to the workload at the local hospital.
I really think the initial drop was a kneejerk reaction to the delay in the Covidity recruitment and without doubt some 'sell on news' traders being caught out by that very unforeseen news. The SP seems to be resilient and is now not showing much of a dent.
Thinking about it, I'm not sure that Scancell can do a partial Safety / Immunogenicity read out on only 16 subjects. The data from those few will be there but to conform with the trial design, technically we may now have to wait until all 40 subjects are 1st dosed, plus 6 weeks for those treated at the end to produce immune responses.
In the great scheme of things it is no big thing.
However, we now await the headline act to take the stage, MODI1. Hopefully the NHS can begin to see a reduction in the commitment to Covid infections and allow staffing levels to return to Clinical Trial duties. If that is now happening our two cancer trials could only be a few weeks away from being up and running.
I personally cannot wait.
The Covidity phase 1 trial will be completed and the data announced we're just going to have to find a little more patience.
Just remember how frustrating this must be for all the Scancell staff who have spent an enormous amount of time and energy developing and setting up to manage three trials at the same time and then to have all three delayed.
As for us investors, our biggest concern is not being privy to the whole operation which leads to worry when deadlines pass and a penny off the share to even more frustration. When all we need is patience. Scancell's day will come and those holding the shares will be rewarded.
Chester.
I do not know whether it would warrant a RNS but first patient dosed with SCOV2 in South Africa trial would definitely be news I would like to hear.
The first patient dosed (with SCOV1 on 5 October 2021) should receive their first and second doses of SCOV2 not before 26 January and not before 23 February 2022 (i.e. day 113 and day 141) respectively.
If the patient has not had their first dose of SCOV2 yet, I would have thought that it would be imperative to the whole trial that this happens soon. AIMHO
This is the link if anyone needs it:-
https://clinicaltrials.gov/ct2/show/NCT05047445?term=covidity&draw=2&rank=1
We never really got any significant news Chester. Nothing tangible anyway. Hence the drop.
If it doesn't start in Q1 .....hmm
Chester, has to be modi1 !!
Lot quieter in here today.
Maybe we should run a sweepstake on what the next significant piece of news will be.
Modi-1 trial lift-off anyone?